Gilead Sciences Inc

$ 68.48 -0.36 (-0.52%)
On watch
Volume: 6,278,756 Avg Vol (1m): 6,213,632
Market Cap $: 87.08 Bil Enterprise Value $: 85.89 Bil
P/E (TTM): 15.11 P/B: 4.00
Earnings Power Value 84.15
Net Current Asset Value -5.35
Tangible Book 1.87
Projected FCF 149.54
Median P/S Value 77.22
Graham Number 13.8
Peter Lynch Value 0
DCF (FCF Based) 145.3
DCF (Earnings Based) 128.96
1Y (-%)

Financial Strength : 6/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 1.05
Cash-To-Debt ranked lower than
100.00% of 859 companies
in the Drug Manufacturers - Major industry.
Industry Max: 91151, Med: 2.03, Min: -0.01
GILD: 1.05
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.15, Med: 1.33, Max: 4122.75
Current: 1.05
0.15
4122.75
Equity-to-Asset 0.35
Equity-to-Asset ranked lower than
79.70% of 788 companies
in the Drug Manufacturers - Major industry.
Industry Max: 1.78, Med: 0.64, Min: -27.83
GILD: 0.35
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: 0.21, Med: 0.6, Max: 0.98
Current: 0.35
0.21
0.98
Debt-to-Equity 1.21
Debt-to-Equity ranked lower than
73.99% of 596 companies
in the Drug Manufacturers - Major industry.
Industry Max: 31.22, Med: 0.32, Min: 0.01
GILD: 1.21
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: 0, Med: 0.44, Max: 2.96
Current: 1.21
0
2.96
Debt-to-EBITDA 2.51
Debt-to-EBITDA ranked higher than
77.37% of 495 companies
in the Drug Manufacturers - Major industry.
Industry Max: 343059.67, Med: 1.92, Min: 0.01
GILD: 2.51
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: 0.33, Med: 1.38, Max: 2.65
Current: 2.51
0.33
2.65
Interest Coverage 7.96
Interest Coverage ranked lower than
65.90% of 648 companies
in the Drug Manufacturers - Major industry.
Industry Max: 2689668, Med: 86.08, Min: 0.01
GILD: 7.96
Ranked among companies with meaningful Interest Coverage only.
Interest Coverage range over the past 10 years
Min: 7.61, Med: 18.37, Max: 50.66
Current: 7.96
7.61
50.66
Piotroski F-Score 7
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 3.03
DISTRESS
GREY
SAFE
Beneish M-Score -2.83
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 26.84%
WACC 7.04%

Profitability & Growth : 9/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % 37.11
Operating Margin ranked higher than
96.13% of 801 companies
in the Drug Manufacturers - Major industry.
Industry Max: 8950, Med: 7.97, Min: -232970.37
GILD: 37.11
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: 37.06, Med: 50.09, Max: 68
Current: 37.11
37.06
68
Net Margin % 26.40
Net Margin ranked higher than
82.17% of 802 companies
in the Drug Manufacturers - Major industry.
Industry Max: 304900, Med: 5.32, Min: -216285.19
GILD: 26.4
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: 17.73, Med: 34.97, Max: 55.48
Current: 26.4
17.73
55.48
ROE % 27.16
ROE ranked higher than
84.62% of 832 companies
in the Drug Manufacturers - Major industry.
Industry Max: 316.96, Med: 5.94, Min: -3119.47
GILD: 27.16
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: 23.53, Med: 45.97, Max: 106.64
Current: 27.16
23.53
106.64
ROA % 9.16
ROA ranked higher than
79.10% of 871 companies
in the Drug Manufacturers - Major industry.
Industry Max: 943.36, Med: 2.88, Min: -1851.14
GILD: 9.16
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: 7.27, Med: 22.13, Max: 42.28
Current: 9.16
7.27
42.28
ROC (Joel Greenblatt) % 241.14
ROC (Joel Greenblatt) ranked higher than
96.14% of 855 companies
in the Drug Manufacturers - Major industry.
Industry Max: 34233.33, Med: 11.23, Min: -2671900
GILD: 241.14
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: 161.64, Med: 218.73, Max: 595.52
Current: 241.14
161.64
595.52
3-Year Total Revenue Growth Rate -12.20
3-Year Revenue Growth Rate ranked higher than
65.31% of 689 companies
in the Drug Manufacturers - Major industry.
Industry Max: 291.9, Med: 5.8, Min: -100
GILD: -7.6
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: -7.6, Med: 37.5, Max: 162.8
Current: -7.6
-7.6
162.8
3-Year Total EBITDA Growth Rate -24.00
3-Year EBITDA Growth Rate ranked lower than
53.41% of 704 companies
in the Drug Manufacturers - Major industry.
Industry Max: 299.6, Med: 7.3, Min: -343.2
GILD: -20
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: 0, Med: 7, Max: 118.3
Current: -20
0
118.3
3-Year EPS w/o NRI Growth Rate -29.50
3-Year EPS w/o NRI Growth Rate ranked lower than
88.39% of 663 companies
in the Drug Manufacturers - Major industry.
Industry Max: 385.8, Med: 8.9, Min: -403.2
GILD: -29.5
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
N/A

» GILD's 30-Y Financials

Financials (Next Earnings Date: 2019-07-25)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:GILD

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Drug Manufacturers » Drug Manufacturers - Major    NAICS : 325412    SIC : 2834
Compare NYSE:BMY LSE:GSK LSE:AZN NAS:CELG NAS:AMGN XPAR:SAN NYSE:LLY XTER:BAYA NYSE:ABBV NAS:BIIB TSE:4519 TSE:4568 TSE:4503 TSE:4578 XMAD:GRF.P HKSE:01093 TSE:4151 SHSE:600436 TSE:4528 MIL:REC
Traded in other countries GILD34.Brazil GIS.Germany
Address 333 Lakeside Drive, Foster City, CA, USA, 94404
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite acquisition boosted Gilead's exposure to cell therapy in oncology.

Ratios

Current vs industry vs history
PE Ratio (TTM) 15.11
PE Ratio ranked higher than
69.30% of 557 companies
in the Drug Manufacturers - Major industry.
Industry Max: 1910, Med: 23.77, Min: 0.06
GILD: 15.11
Ranked among companies with meaningful PE Ratio only.
PE Ratio range over the past 10 years
Min: 6.68, Med: 15.05, Max: 64.34
Current: 15.11
6.68
64.34
Forward PE Ratio 10.22
Forward P/E ranked higher than
90.09% of 111 companies
in the Drug Manufacturers - Major industry.
Industry Max: 322.58, Med: 21.6, Min: 5.03
GILD: 10.22
Ranked among companies with meaningful Forward P/E only.
N/A
PE Ratio without NRI 15.11
PE without NRI ranked higher than
70.14% of 556 companies
in the Drug Manufacturers - Major industry.
Industry Max: 2125, Med: 24.2, Min: 0.06
GILD: 15.11
Ranked among companies with meaningful PE without NRI only.
PE without NRI range over the past 10 years
Min: 6.68, Med: 15.05, Max: 64.34
Current: 15.11
6.68
64.34
Price-to-Owner-Earnings 17.43
Price-to-Owner-Earnings ranked higher than
91.67% of 324 companies
in the Drug Manufacturers - Major industry.
Industry Max: 3160, Med: 31.95, Min: 0.17
GILD: 17.43
Ranked among companies with meaningful Price-to-Owner-Earnings only.
Price-to-Owner-Earnings range over the past 10 years
Min: 5.52, Med: 13.03, Max: 54.5
Current: 17.43
5.52
54.5
PB Ratio 4.00
PB Ratio ranked lower than
62.15% of 819 companies
in the Drug Manufacturers - Major industry.
Industry Max: 227.39, Med: 2.64, Min: 0.05
GILD: 4
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 3.64, Med: 5.99, Max: 12.5
Current: 4
3.64
12.5
PS Ratio 3.98
PS Ratio ranked higher than
74.97% of 775 companies
in the Drug Manufacturers - Major industry.
Industry Max: 9105.26, Med: 3.1, Min: 0.03
GILD: 3.98
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 2.95, Med: 4.49, Max: 12.5
Current: 3.98
2.95
12.5
Price-to-Free-Cash-Flow 13.41
Price-to-Free-Cash-Flow ranked higher than
91.61% of 298 companies
in the Drug Manufacturers - Major industry.
Industry Max: 3143.75, Med: 30.84, Min: 0.23
GILD: 13.41
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
Price-to-Free-Cash-Flow range over the past 10 years
Min: 5.45, Med: 11.89, Max: 48.02
Current: 13.41
5.45
48.02
Price-to-Operating-Cash-Flow 11.72
Price-to-Operating-Cash-Flow ranked higher than
92.35% of 392 companies
in the Drug Manufacturers - Major industry.
Industry Max: 14229.87, Med: 22, Min: 0.23
GILD: 11.72
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 5.24, Med: 11.14, Max: 45.09
Current: 11.72
5.24
45.09
EV-to-EBIT 9.36
EV-to-EBIT ranked higher than
88.81% of 572 companies
in the Drug Manufacturers - Major industry.
Industry Max: 1015380.11, Med: 17.85, Min: 0.13
GILD: 9.36
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: 5.3, Med: 9.4, Max: 32.5
Current: 9.36
5.3
32.5
EV-to-EBITDA 8.11
EV-to-EBITDA ranked higher than
88.61% of 597 companies
in the Drug Manufacturers - Major industry.
Industry Max: 341528.02, Med: 15.24, Min: 0.12
GILD: 8.11
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: 5, Med: 8.6, Max: 30.2
Current: 8.11
5
30.2
EV-to-Revenue 3.85
EV-to-Revenue ranked higher than
75.97% of 795 companies
in the Drug Manufacturers - Major industry.
Industry Max: 23858.8, Med: 3.24, Min: 0.03
GILD: 3.85
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 3.1, Med: 4.9, Max: 13.1
Current: 3.85
3.1
13.1
PEG Ratio 0.88
PEG Ratio ranked higher than
88.96% of 317 companies
in the Drug Manufacturers - Major industry.
Industry Max: 1472, Med: 1.93, Min: 0.07
GILD: 0.88
Ranked among companies with meaningful PEG Ratio only.
PEG Ratio range over the past 10 years
Min: 0.11, Med: 0.45, Max: 3.85
Current: 0.88
0.11
3.85
Shiller PE Ratio 13.76
Shiller PE Ratio ranked higher than
95.63% of 252 companies
in the Drug Manufacturers - Major industry.
Industry Max: 1460.4, Med: 32.75, Min: 0.08
GILD: 13.76
Ranked among companies with meaningful Shiller PE Ratio only.
Shiller PE Ratio range over the past 10 years
Min: 12.5, Med: 38.04, Max: 152
Current: 13.76
12.5
152
Current Ratio 3.62
Current Ratio ranked lower than
79.88% of 855 companies
in the Drug Manufacturers - Major industry.
Industry Max: 413.44, Med: 2.39, Min: 0.02
GILD: 3.62
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 1.08, Med: 6.81, Max: 57.67
Current: 3.62
1.08
57.67
Quick Ratio 3.53
Quick Ratio ranked lower than
77.08% of 855 companies
in the Drug Manufacturers - Major industry.
Industry Max: 413.44, Med: 1.87, Min: 0.02
GILD: 3.53
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 0.82, Med: 6.28, Max: 57.67
Current: 3.53
0.82
57.67
Days Inventory 64.85
Days Inventory ranked higher than
78.01% of 755 companies
in the Drug Manufacturers - Major industry.
Industry Max: 950.68, Med: 119.8, Min: 0.2
GILD: 64.85
Ranked among companies with meaningful Days Inventory only.
Days Inventory range over the past 10 years
Min: 60.73, Med: 185.96, Max: 231.54
Current: 64.85
60.73
231.54
Days Sales Outstanding 53.69
Days Sales Outstanding ranked higher than
64.16% of 770 companies
in the Drug Manufacturers - Major industry.
Industry Max: 864.61, Med: 81.76, Min: 0.1
GILD: 53.69
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 53.69, Med: 66.93, Max: 84.93
Current: 53.69
53.69
84.93
Days Payable 43.79
Days Payable ranked higher than
58.31% of 758 companies
in the Drug Manufacturers - Major industry.
Industry Max: 952.38, Med: 76.32, Min: 0.04
GILD: 43.79
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 43.79, Med: 132.04, Max: 207.21
Current: 43.79
43.79
207.21

Dividend & Buy Back

Current vs industry vs history
Dividend Yield % 3.52
Trailing Dividend Yield ranked higher than
96.94% of 752 companies
in the Drug Manufacturers - Major industry.
Industry Max: 25.84, Med: 1.54, Min: 0.04
GILD: 3.52
Ranked among companies with meaningful Trailing Dividend Yield only.
Trailing Dividend Yield range over the past 10 years
Min: 0.36, Med: 2.63, Max: 3.76
Current: 3.52
0.36
3.76
Dividend Payout Ratio 0.52
Dividend Payout Ratio ranked higher than
74.63% of 477 companies
in the Drug Manufacturers - Major industry.
Industry Max: 68, Med: 0.3, Min: 0.02
GILD: 0.52
Ranked among companies with meaningful Dividend Payout Ratio only.
Dividend Payout Ratio range over the past 10 years
Min: 0.11, Med: 0.37, Max: 0.59
Current: 0.52
0.11
0.59
3-Year Dividend Growth Rate (Per Share) 20.90
3-Year Dividend Growth Rate ranked lower than
100.00% of 299 companies
in the Drug Manufacturers - Major industry.
Industry Max: 114, Med: 7.4, Min: -100
GILD: 20.9
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
3-Year Dividend Growth Rate range over the past 10 years
Min: 0, Med: 0, Max: 20.9
Current: 20.9
0
20.9
Forward Dividend Yield % 3.66
Forward Dividend Yield ranked higher than
96.94% of 719 companies
in the Drug Manufacturers - Major industry.
Industry Max: 25.84, Med: 1.66, Min: 0.04
GILD: 3.66
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield-on-Cost (5-Year) % 3.52
Yield-on-Cost (5y) ranked higher than
92.35% of 745 companies
in the Drug Manufacturers - Major industry.
Industry Max: 42.46, Med: 2.12, Min: 0.03
GILD: 3.52
Ranked among companies with meaningful Yield-on-Cost (5y) only.
Yield-on-Cost (5y) range over the past 10 years
Min: 0.36, Med: 2.63, Max: 3.76
Current: 3.52
0.36
3.76
3-Year Share Buyback Rate 3.40
3-Year Share Buyback Rate ranked higher than
98.25% of 571 companies
in the Drug Manufacturers - Major industry.
Industry Max: 100, Med: -5.3, Min: -815
GILD: 3.4
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -25.6, Med: -2.6, Max: 6.1
Current: 3.4
-25.6
6.1

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 36.62
Price-to-Tangible-Book ranked lower than
100.00% of 749 companies
in the Drug Manufacturers - Major industry.
Industry Max: 972.22, Med: 3.33, Min: 0.05
GILD: 36.62
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 1.51, Med: 8.67, Max: 214.73
Current: 36.62
1.51
214.73
Price-to-Projected-FCF 0.46
Price-to-Intrinsic-Value-Projected-FCF ranked higher than
97.86% of 374 companies
in the Drug Manufacturers - Major industry.
Industry Max: 209, Med: 2.11, Min: 0.05
GILD: 0.46
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 0.42, Med: 1.77, Max: 20.83
Current: 0.46
0.42
20.83
Price-to-DCF (Earnings Based) 0.53
Price-to-Intrinsic-Value-DCF (Earnings Based) ranked higher than
86.36% of 110 companies
in the Drug Manufacturers - Major industry.
Industry Max: 27.76, Med: 1.36, Min: 0.14
GILD: 0.53
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
Price-to-Intrinsic-Value-DCF (Earnings Based) range over the past 10 years
Min: 0.5, Med: 1.03, Max: 3.84
Current: 0.53
0.5
3.84
Price-to-Median-PS-Value 0.89
Price-to-Median-PS-Value ranked higher than
64.33% of 743 companies
in the Drug Manufacturers - Major industry.
Industry Max: 238.36, Med: 0.94, Min: 0.01
GILD: 0.89
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.68, Med: 2.5, Max: 45
Current: 0.89
0.68
45
Price-to-Graham-Number 4.96
Price-to-Graham-Number ranked higher than
60.29% of 481 companies
in the Drug Manufacturers - Major industry.
Industry Max: 36.65, Med: 1.81, Min: 0.02
GILD: 4.96
Ranked among companies with meaningful Price-to-Graham-Number only.
Price-to-Graham-Number range over the past 10 years
Min: 1.56, Med: 3.54, Max: 15.75
Current: 4.96
1.56
15.75
Earnings Yield (Joel Greenblatt) % 10.67
Earnings Yield (Greenblatt) ranked higher than
92.62% of 867 companies
in the Drug Manufacturers - Major industry.
Industry Max: 769.23, Med: 3.31, Min: -333.33
GILD: 10.67
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: 3.1, Med: 10.6, Max: 18.8
Current: 10.67
3.1
18.8
Forward Rate of Return (Yacktman) % 17.52
Forward Rate of Return ranked higher than
98.57% of 421 companies
in the Drug Manufacturers - Major industry.
Industry Max: 559.55, Med: 8.96, Min: -1635.32
GILD: 17.52
Ranked among companies with meaningful Forward Rate of Return only.
Forward Rate of Return range over the past 10 years
Min: 13.9, Med: 25.2, Max: 33.3
Current: 17.52
13.9
33.3

More Statistics

Revenue (TTM) (Mil) $ 22,320
EPS (TTM) $ 4.53
Beta 1.14
Volatility % 27.18
52-Week Range $ 60.32 - 79.61
Shares Outstanding (Mil) 1,271.55

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 7
Positive ROA Y
Positive CFROA Y
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy Y
Less Shares Outstanding yoy Y
Higher Gross Margin yoy N
Higher Asset Turnover yoy N